The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated•Originally published 9 May 2026•Updated 10 May 2026•

1 min read

Zoetis Shares Hit Five-Year Low Amid Competitive Pressures and Earnings Miss

Key Facts

1Zoetis shares have declined 37% year-to-date, reaching a five-year low.

2The company reported rare misses on both top and bottom lines, driven by US companion animal weakness and generics pressure.

25 days ago

Version History

Version 125 days ago

What changed: Added Q1 US companion animal sales data, identified specific drugs under generic pressure, and noted the investment rating downgrade.

Zoetis is grappling with significant financial headwinds as its stock price plummeted 37% year-to-date, reaching its lowest level in five years. The company reported rare misses on both revenue and earnings, highlighted by an 11% year-over-year decline in US companion animal sales during the first quarter. Legacy drugs, specifically Convenia and Cerenia, have been heavily impacted by patent expirations and rising competition from generic alternatives. Despite sustained growth in the international and livestock segments, these pressures have led to a formal investment rating downgrade for the stock. While Zoetis maintained its 2026 revenue guidance of $9.68 billion to $9.96 billion, investors remain cautious. Analysts are closely monitoring the firm's ability to defend profitability margins amid structural market shifts and pricing competition.